Oculis Holding, a listed global biopharmaceutical company focused on innovations to address unmet medical needs in ophthalmology and neuro-ophthalmology, has priced an oversubscribed US$110m financing to accelerate Privosegtor development. The…
Switzerland: Oculis prices US$110m financing to accelerate development of Privosegtor
…
…






